EA037070B9 - Комбинация гликозаминогликанов и антацидного агента и содержащая ее композиция - Google Patents

Комбинация гликозаминогликанов и антацидного агента и содержащая ее композиция

Info

Publication number
EA037070B9
EA037070B9 EA201890842A EA201890842A EA037070B9 EA 037070 B9 EA037070 B9 EA 037070B9 EA 201890842 A EA201890842 A EA 201890842A EA 201890842 A EA201890842 A EA 201890842A EA 037070 B9 EA037070 B9 EA 037070B9
Authority
EA
Eurasian Patent Office
Prior art keywords
combination
chondroitin sulfate
sodium
magaldrate
pharmaceutically acceptable
Prior art date
Application number
EA201890842A
Other languages
English (en)
Other versions
EA201890842A1 (ru
EA037070B1 (ru
Inventor
Анджело Пиццони
Паоло Пиццони
Original Assignee
Афарм С.Р.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITUB2015A004158A external-priority patent/ITUB20154158A1/it
Application filed by Афарм С.Р.Л. filed Critical Афарм С.Р.Л.
Publication of EA201890842A1 publication Critical patent/EA201890842A1/ru
Publication of EA037070B1 publication Critical patent/EA037070B1/ru
Publication of EA037070B9 publication Critical patent/EA037070B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к комбинации для профилактики и лечения повышенной кислотности желудочного сока и желудочно-пищеводного рефлюкса, содержащей гиалуроновую кислоту или ее фармацевтически приемлемую соль, хондроитинсульфат или его фармацевтически приемлемую соль, магалдрат и биоадгезивный агент. Гиалуроновая кислота и хондроитинсульфат находятся в форме солей щелочных металлов, в частности натрия. Комбинация является фиксированной комбинацией, в которой хондроитинсульфат натрия присутствует в количестве в 1,5-5 раз большем, а магалдрат - в количестве в 3-20 раз большем, чем гиалуронат натрия. Предпочтительно соотношение гиалуронат натрия:хондроитинсульфат натрия:магалдрат составляет 1:2,5:(10-13). Комбинация входит в состав фармацевтической композиции для профилактики и лечения повышенной кислотности желудочного сока и желудочно-пищеводного рефлюкса, которая дополнительно содержит по меньшей мере один фармацевтически приемлемый носитель или эксципиент. Фармацевтическая композиция представлена в единичной дозированной форме, содержащей 30-100 мг гиалуроната натрия, 80-200 мг хондроитинсульфата натрия и 400-600 мг магалдрата и может дополнительно содержать по меньшей мере один биоадгезивный полимер в суммарном количестве 100-400 мг. Указанный биоадгезивный полимер выбран из группы, состоящей из полоксамеров, сополимеров этиленоксида и пропиленоксида, винилпирролидоновых полимеров и производных целлюлозы.
EA201890842A 2015-10-01 2016-09-30 Комбинация гликозаминогликанов и антацидного агента и содержащая ее композиция EA037070B9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITUB2015A004158A ITUB20154158A1 (it) 2015-10-01 2015-10-01 Associazione di glicosamminoglicani e magaldrato e composizioni che la contengono.
ITUA2016A002869A ITUA20162869A1 (it) 2015-10-01 2016-04-26 Associazione di glicosamminoglicani e un agente antiacido e composizioni che la contengono.
PCT/IB2016/001423 WO2017055909A1 (en) 2015-10-01 2016-09-30 Combination of glycosaminoglycans and an antacid agent and compositions thereof

Publications (3)

Publication Number Publication Date
EA201890842A1 EA201890842A1 (ru) 2018-09-28
EA037070B1 EA037070B1 (ru) 2021-02-02
EA037070B9 true EA037070B9 (ru) 2021-03-29

Family

ID=57288470

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890842A EA037070B9 (ru) 2015-10-01 2016-09-30 Комбинация гликозаминогликанов и антацидного агента и содержащая ее композиция

Country Status (8)

Country Link
US (1) US11116786B2 (ru)
EP (1) EP3240550B1 (ru)
KR (1) KR20180081508A (ru)
CA (1) CA2999411A1 (ru)
EA (1) EA037070B9 (ru)
MX (1) MX2018003975A (ru)
PL (1) PL3240550T3 (ru)
WO (1) WO2017055909A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600101413A1 (it) 2016-10-10 2018-04-10 Sofar Swiss S A Composizione liquida per uso nel trattamento del reflusso gastroesofageo
IT201700124434A1 (it) * 2017-10-31 2019-05-01 Sofar Swiss Sa Compressa da succhiare e/o sciogliere in bocca a base di acido ialuronico e condroitina solfato e loro sali per uso nel trattamento di una sottopopolazione di pazienti GERD.
IT201700124424A1 (it) * 2017-10-31 2019-05-01 Sofar Swiss Sa Compressa da succhiare e/o sciogliere in bocca a base di acido ialuronico e condroitina solfato e loro sali
IT201800006400A1 (it) 2018-06-18 2019-12-18 Composizione per le patologie gastriche ed esofagee
IT201900024958A1 (it) * 2019-12-20 2021-06-20 Neilos S R L Composizione per la protezione della mucosa gastro-intestinale e per la prevenzione e il trattamento di patologie ad essa associate
IT202000016531A1 (it) * 2020-07-08 2022-01-08 Italian Devices S R L Composizioni mucoadesive e filmogene
IT202000022477A1 (it) * 2020-09-23 2022-03-23 Sofar Swiss Sa Composizioni comprendenti una condroitina vegetale o un suo analogo e loro uso nel trattamento disturbi della mucosa del tratto orale, faringo-laringeo e/o gastro-esofageo
IT202000022471A1 (it) * 2020-09-23 2022-03-23 Sofar Swiss Sa Composizioni comprendenti una condroitina vegetale o un suo analogo e loro uso nel trattamento disturbi della mucosa del tratto orale, faringo-laringeo e/o gastro-esofageo
WO2022097036A1 (en) * 2020-11-03 2022-05-12 Neilos S.r.l. Composition for use in the prevention and treatment of diseases of the gastrointestinal system and of the related symptoms
IT202100021995A1 (it) * 2021-08-27 2023-02-27 Neilos S R L Composizione per la prevenzione e/o il trattamento delle patologie gastriche ed esofagee
IT202100021992A1 (it) * 2021-08-27 2023-02-27 Neilos S R L Composizione per la prevenzione e/o il trattamento delle patologie gastriche ed esofagee

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676984A (en) * 1985-08-14 1987-06-30 American Home Products Corp. Rehydratable antacid composition
WO2010136872A2 (en) * 2009-05-25 2010-12-02 Pharcoterm S.R.L. Use of a glycosaminoglycan fixed combination and chewable composition comprising said fixed combination
US20140107064A1 (en) * 2008-05-13 2014-04-17 Apharm S.R.L. Glycosaminoglycan oral use and compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19859231A1 (de) * 1998-12-21 2000-06-29 Kurt Heinz Bauer Schäumende Antacida-Suspensionstabletten
ITMI20012200A1 (it) 2001-10-22 2003-04-22 Ibsa Inst Biochimique Sa Processo per la preparazione di condroitin solfati dal polisaccaride k4 e prodotti ottenuti
TWM399771U (en) 2010-10-29 2011-03-11 Jian Xue Qin Y-axis aligned twin spindle C-model vertical machining center with dual Z-axis function

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676984A (en) * 1985-08-14 1987-06-30 American Home Products Corp. Rehydratable antacid composition
US20140107064A1 (en) * 2008-05-13 2014-04-17 Apharm S.R.L. Glycosaminoglycan oral use and compositions
WO2010136872A2 (en) * 2009-05-25 2010-12-02 Pharcoterm S.R.L. Use of a glycosaminoglycan fixed combination and chewable composition comprising said fixed combination

Also Published As

Publication number Publication date
EP3240550A1 (en) 2017-11-08
EP3240550B1 (en) 2019-04-10
EA201890842A1 (ru) 2018-09-28
US20180280426A1 (en) 2018-10-04
PL3240550T3 (pl) 2019-10-31
CA2999411A1 (en) 2017-04-06
US11116786B2 (en) 2021-09-14
MX2018003975A (es) 2018-09-06
KR20180081508A (ko) 2018-07-16
EA037070B1 (ru) 2021-02-02
WO2017055909A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
EA037070B9 (ru) Комбинация гликозаминогликанов и антацидного агента и содержащая ее композиция
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2012075362A3 (en) Chemokine cxcr4 receptor modulators and used related thereto
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
NZ741318A (en) Compound for treating or preventing hyperuricemia or gout
MX345227B (es) Composiciones farmaceuticas solidas que contienen un inhibidor de la integrasa.
NZ727834A (en) Fast acting orally disintegrating film
WO2010042391A3 (en) Hiv integrase inhibitors
PH12015502406A1 (en) Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof
PH12020550009A1 (en) Pharmaceutical preparation and preparation method therefor
FI2034956T4 (fi) Matalan viskositeetin omaavia glykosaminoglykaaneja käsittäviä koostumuksia ja mainitun koostumuksen käyttö kroonisen kystiitin terapiassa
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
JOP20220075A1 (ar) مثبطات عامل d المكمل عن طريق الفم
JP2016512247A5 (ru)
NZ611145A (en) Peg or peg block copolymers for treating colorectal cancer
MX2020008360A (es) Forma cristalina de bictegravir sodico.
MX2011003535A (es) Composiciones de virus de herpes bovino-1, vacunas, y metodos.
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
WO2019004788A3 (ko) 브라우쏘칼콘 a를 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약학 조성물
MX2022006940A (es) Composiciones farmaceuticas.
MX2021015441A (es) Formas cristalinas de cabotegravir de sodio.
JOP20210198A1 (ar) تركيبة دوائية تشتمل على ماسيتينتان لعلاج ارتفاع ضغط الدم الرئوي الانصمامي الخثاري المزمن
SI2914599T1 (en) The solid salt form as alpha-6-mPEG6-O-hydroxycodone as opioid agonists and its use

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent